Page 2 - Gsk

India Inc gets back to office cautiously, even as many MNCs remain shut

Many are testing hybrid models to ensure safety and hygiene; seat-booking module introduced in some companies

COVAX gains access to 2 billion doses of vaccines for 190 member economies

First deliveries are expected to begin in the first quarter of 2021 depending upon regulatory approvals and readiness of countries for delivery

Sanofi-GSK delay Covid-19 vaccine to late 2021 in setback to global fight

The two companies said they planned to start another study next February, hoping to come up with a more effective vaccine

Sputnik V developers offer to share tech with Sanofi-GSK amid vaccine delay

In late November, the Sputnik V developers also offered foreign vaccine producers their help

Sanofi, GSK to provide 200 mn doses of Covid-19 vaccine to global alliance

The facility is part of COVAX, a coalition of governments, health organisations, businesses and charities working to accelerate the development of Covid-19 vaccines

Sanofi and GSK launch trial for protein-based coronavirus vaccine

PARIS (Reuters) - French drugmaker Sanofi and its British peer GSK have started a clinical trial for a protein-based COVID-19 vaccine candidate, as pharmaceutical companies race to develop treatments

US to pay Sanofi, GSK $2.1 bn for Covid-19 vaccine to cover 50 mn people

A Sanofi executive said the companies had not yet agreed with the US on a specific price for additional doses

US pledges up to $2.1 billion for Sanofi, GlaxoSmithKline Covid-19 vaccine

Glaxo shares traded 1.6 per cent higher in London, with Sanofi up 1.4 per cent in Paris

GSK profit misses as vaccine sales disappoint, stockpiling eases

The company said it still expects adjusted earnings per share for the year to decline in the range of 1% to 4%

GSK buys 10% stake of German biotech firm CureVac in $164-million deal

GSK and CureVac, backed by Bill Gates, will work on developing up to five so-called mRNA-based vaccines and monoclonal antibodies (mAbs) for infectious diseases, they said.

GSK in quest to be best, not first, in race for coronavirus vaccine

GSK, which is in seven collaborations with institutions or firms globally, only entered the clinical trial stage with one project on Friday

GSK to produce 1 billion doses of coronavirus vaccine booster in 2021

The British drugmaker is working on its own COVID vaccine with Sanofi

GSK Pharma: Near term headwinds may keep stock prices under pressure

April sales were the worst among top drug players

Street signs: Banking stocks under pressure, FPI tally gets skewed and more

The performance of banking stocks is likely to weigh on the markets

Market Ahead, May 7: Top factors that could guide markets today

Hindustan Unilever will be in focus today as UK-based GSK will offload shares worth Rs 26,000 crore in the FMGC major

Coronavirus impact: Top pharma companies fare better during lockdown

New launches stagnate as fresh prescriptions dry up

Glaxo Consumer reports 6% rise in profit before tax for December quarter

The firm's operating revenue stood at Rs 1,159 crore - up 3.7 per cent YoY from Rs 1,117 crore

Pfizer planning initial public offering of GSK consumer venture in four yrs

Albert Bourla, CEO of Pfizer, discussed the time frame for the IPO at the JPMorgan Healthcare Conference in San Francisco on Tuesday

Legacy pharma brands spin gold for GSK, Pfizer; keep newcomers off the turf

Repositioning an old brand helps expand the footprint, say analysts

GSK credits STEER for Horlicks technology after year-long IP battle

STEER which was founded in 1993 by Padmanabhan has 5 global offices and 10 satellite offices, serving over 39 countries. It employs over 500 engineers, scientists and technicians across the globe